These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 20598943)

  • 21. [Treatment of invasive fungal infections with voriconazole. Evaluation of experience with compassionate use of voriconazole in Spain].
    Díaz Pedroche C; Cisneros JM; Lumbreras C; Aguado JM;
    Rev Esp Quimioter; 2005 Jun; 18(2):149-58. PubMed ID: 16130037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.
    Metcalf SC; Dockrell DH
    J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
    Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.
    Groll AH; Walsh TJ
    Mycoses; 2006; 49 Suppl 1():7-16. PubMed ID: 16961576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recommendations for the treatment of established fungal infections.
    Thursky KA; Playford EG; Seymour JF; Sorrell TC; Ellis DH; Guy SD; Gilroy N; Chu J; Shaw DR
    Intern Med J; 2008 Jun; 38(6b):496-520. PubMed ID: 18588522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Invasive fungal infection--laboratory diagnosis and antifungal treatment.
    Shao PL; Huang LM; Hsueh PR
    J Microbiol Immunol Infect; 2006 Jun; 39(3):178-88. PubMed ID: 16783447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selection criteria for antifungals: the right patients and the right reasons.
    Chandrasekar P
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():17-20. PubMed ID: 16707246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Newer antifungal agents for invasive fungal infections in patients with haematological malignancy.
    Rogers TR; Frost S
    Br J Haematol; 2009 Mar; 144(5):629-41. PubMed ID: 19120371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.
    Slavin MA; Szer J; Grigg AP; Roberts AW; Seymour JF; Sasadeusz J; Thursky K; Chen SC; Morrissey CO; Heath CH; Sorrell T
    Intern Med J; 2004 Apr; 34(4):192-200. PubMed ID: 15086700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liposomal amphotericin B: what is its role in 2008?
    Lanternier F; Lortholary O
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():71-83. PubMed ID: 18430132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in antifungal prophylaxis and empiric therapy in patients with hematologic malignancies.
    Murali S; Langston A
    Transpl Infect Dis; 2009 Dec; 11(6):480-90. PubMed ID: 19725908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients.
    Neofytos D; Fishman JA; Horn D; Anaissie E; Chang CH; Olyaei A; Pfaller M; Steinbach WJ; Webster KM; Marr KA
    Transpl Infect Dis; 2010 Jun; 12(3):220-9. PubMed ID: 20113459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Invasive mycoses: strategies for effective management.
    Kontoyiannis DP
    Am J Med; 2012 Jan; 125(1 Suppl):S25-38. PubMed ID: 22196206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections.
    Horn DL; Fishman JA; Steinbach WJ; Anaissie EJ; Marr KA; Olyaei AJ; Pfaller MA; Weiss MA; Webster KM; Neofytos D
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):407-14. PubMed ID: 17888614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamic implications for use of antifungal agents.
    Lewis RE
    Curr Opin Pharmacol; 2007 Oct; 7(5):491-7. PubMed ID: 17616480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients.
    Hamza NS; Ghannoum MA; Lazarus HM
    Bone Marrow Transplant; 2004 Sep; 34(5):377-89. PubMed ID: 15247928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine.
    Chamilos G; Kontoyiannis DP
    Curr Opin Infect Dis; 2006 Aug; 19(4):380-5. PubMed ID: 16804387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antifungal combination therapy in invasive fungal infections].
    Gellen-Dautremer J; Lanternier F; Dannaoui E; Lortholary O
    Rev Med Interne; 2010 Jan; 31(1):72-81. PubMed ID: 19767130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Echinocandins: a wealth of choice--how clinically different are they?
    Zaas AK
    Curr Opin Infect Dis; 2008 Aug; 21(4):426-32. PubMed ID: 18594297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invasive fungal infections: the challenge continues.
    Gullo A
    Drugs; 2009; 69 Suppl 1():65-73. PubMed ID: 19877737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.